These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 2055558

  • 1. Fibrinolytic studies in 13 unrelated families with factor XII deficiency.
    Rodeghiero F, Castaman G, Ruggeri M, Cazzavillan M, Ferracin G, Dini E.
    Haematologica; 1991; 76(1):28-32. PubMed ID: 2055558
    [Abstract] [Full Text] [Related]

  • 2. Factor XII-dependent fibrinolysis: a double function of plasma kallikrein and the occurrence of a previously undescribed factor XII- and kallikrein-dependent plasminogen proactivator.
    Kluft C, Trumpi-Kalshoven MM, Jie AF, Veldhuyzen-Stolk EC.
    Thromb Haemost; 1979 Jun 30; 41(4):756-73. PubMed ID: 483248
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Analysis of intrinsic fibrinolysis in human plasma induced by dextran sulfate.
    Tsuda H, Miyata T, Iwanaga S, Yamamoto T.
    Thromb Haemost; 1992 Apr 02; 67(4):440-4. PubMed ID: 1631792
    [Abstract] [Full Text] [Related]

  • 5. Intrinsic plasma fibrinolysis: involvement of urokinase-related activity in the factor XII-independent plasminogen proactivator pathway.
    Kluft C, Wijngaards G, Jie AF.
    J Lab Clin Med; 1984 Mar 02; 103(3):408-19. PubMed ID: 6199446
    [Abstract] [Full Text] [Related]

  • 6. Contact system dependent fibrinolytic activity in vivo: observations in healthy subjects and factor XII deficient patients.
    Levi M, Hack CE, de Boer JP, Brandjes DP, Büller HR, ten Cate JW.
    Agents Actions Suppl; 1992 Mar 02; 38 ( Pt 2)():292-8. PubMed ID: 1462834
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Thromboembolism and bleeding tendency in congenital factor XII deficiency--a study on 74 subjects from 14 Swiss families.
    Lämmle B, Wuillemin WA, Huber I, Krauskopf M, Zürcher C, Pflugshaupt R, Furlan M.
    Thromb Haemost; 1991 Feb 12; 65(2):117-21. PubMed ID: 1905067
    [Abstract] [Full Text] [Related]

  • 11. Kallikrein and prekallikrein levels in a large number of congenital clotting deficiencies and abnormalities.
    Patrassi GM, Martinelli S, Vianello C, Girolami A.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982 Feb 12; 109(4):644-54. PubMed ID: 6184289
    [Abstract] [Full Text] [Related]

  • 12. An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein.
    Binnema DJ, Dooijewaard G, Turion PN.
    Thromb Haemost; 1991 Feb 12; 65(2):144-8. PubMed ID: 1905069
    [Abstract] [Full Text] [Related]

  • 13. Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen--levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator.
    Jespersen J, Kluft C.
    Thromb Haemost; 1985 Aug 30; 54(2):454-9. PubMed ID: 2417350
    [Abstract] [Full Text] [Related]

  • 14. [Congenital deficiency of factor Xii and spontaenous venous thrombosis treated with urokinase].
    Cornudella R, Moreno JA, Aguado MJ, Ansó V, Revilla JM, Calvo MT, Gutiérrez M.
    Sangre (Barc); 1995 Jun 30; 40(3):219-22. PubMed ID: 7570275
    [Abstract] [Full Text] [Related]

  • 15. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation.
    Weiss AS, Gallin JI, Kaplan AP.
    J Clin Invest; 1974 Feb 30; 53(2):622-33. PubMed ID: 11344577
    [Abstract] [Full Text] [Related]

  • 16. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro.
    Tanaka A, Suzuki Y, Sugihara K, Kanayama N, Urano T.
    Life Sci; 2009 Jul 31; 85(5-6):220-5. PubMed ID: 19500599
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S.
    Dan Med Bull; 1993 Sep 31; 40(4):383-408. PubMed ID: 8222763
    [Abstract] [Full Text] [Related]

  • 20. Hageman-factor-dependent fibrinolysis: generation of fibrinolytic activity by the interaction of human activated factor XI and plasminogen.
    Mandle RJ, Kaplan AP.
    Blood; 1979 Oct 31; 54(4):850-62. PubMed ID: 89876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.